PharmAla Biotech Holdings Inc.

PharmAla Biotech Holdings Inc. is a Canadian biotechnology company dedicated to the research, development, manufacturing, and sale of clinical-grade MDMA and novel MDXX class molecules. Headquartered in Toronto, Ontario, the company's mission is to ensure a steady and accessible supply of clinical-grade Active Pharmaceutical Ingredient (API) for the scientific research community and to develop improved MDMA-based compounds. PharmAla operates as a "regulatory-first" organization, emphasizing strong relationships with regulators to advance the psychedelics industry.

The company's key products include LaNeo™ MDMA, its clinical-grade MDMA, and novel MDXX compounds such as ALA-002, which is designed with an improved safety profile. PharmAla supplies MDMA for clinical trials and patient treatments in jurisdictions like Canada and Australia, and is engaged in preclinical research on novel chemical entities aimed at increasing the safety of MDMA and its analogs. They also develop novel analogs for various medical conditions, including social anxiety and brain trauma.

Led by CEO Nicholas Kadysh, PharmAla Biotech is positioned as a leading global producer and supplier of MDMA for clinical use. Recent developments include its readiness to supply the U.S. Expanded Access Pathway for MDMA following a Presidential Executive Order in April 2026. The company has also initiated GMP manufacturing of its lead drug candidate, ALA-002, with patient dosing anticipated in 2026. Furthermore, its Australian joint venture, Cortexa, has commenced local manufacturing of GMP LaNeo MDMA capsules, establishing a reliable supply chain in the region. PharmAla is actively involved in supplying MDMA for a Canadian study on neuropathic pain.